Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ImmunityBio, Inc. (NASDAQ: IBRX) publicly traded securities between January 19, 2026 and March 24, 2026, all dates inclusive ...

TCU's overtime win over Washington ended Sunday at 11:17 p.m. Postgame pressers stretched past midnight. Marta Suarez had ...

Hengrui Pharma (Hengrui), and Braveheart Bio today announced results from a multi-center, randomized, open-label Phase 2 dose-ranging study evaluating HRS-1893 (also known as BHB-1893), an ...

The transfer portal continues to churn out highly talented hoopers. Kentucky has been linked to plenty of them, especially backcourt players. Zoom meetings and visits are currently in the works as the ...

Company to pursue Phase 3 development strategy designed to deliver best-in-class efficacy with a high-dose quarterly regimen ...

PALI-2108 demonstrated favorable safety and tolerability with no serious adverse events after two weeks of treatment in a difficult-to-treat ...

The phrase "exotic GEOs" is common shorthand in performance marketing for markets considered too unstable, too complex, or ...

Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 ...

As players become more transient in the NIL era, it's coaches like May and Dan Hurley who are often the main attractions.

The Arizona State tackle has tons of potential at right tackle.

PALI-2108 demonstrated favorable safety and tolerability with no serious adverse events after two weeks of treatment in a difficult-to-treat populationPhase 1b data demonstrate endoscopic improvement ...